MAPPED study design: A 6month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging

Contemporary Clinical Trials

Volumn 34, Issue 1, 2013, Pages 80-89

  Robertson, N L ^a,b   Moore, C M ^a,c   Ambler, G ^a   Bott, S R J ^d   Freeman, A ^b   Gambarota, G ^e   Jameson, C ^b   Mitra, A V ^f   Whitcher, B ^g   Winkler, M ^h   Kirkham, A ^b   Allen, C ^b   Emberton, M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^d FRIMLEY PARK HOSPITAL   (United Kingdom)

^e UNIVERSITÉ DE RENNES 1   (France)

^f UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^g Mango Solutions   (United Kingdom)

^h IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Dutasteride; Magnetic resonance imaging; Prostate cancer; Randomised controlled trial

Indexed keywords

DUTASTERIDE; PLACEBO;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME; ULTRASOUND;

5-ALPHA REDUCTASE INHIBITORS; ADULT; AZASTEROIDS; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; ORGAN SIZE; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84870484207     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2012.10.003     Document Type: Article

References (12)

1. Marks L.S. 5 alpha reductase: history and clinical importance. Rev Urol 2004, 6(Suppl. 9):S11-S21.
2. Thomas L.N., Lazier C.B., Gupta R., Norman R.W., Troyer D.A., O'Brien S.P., et al. Differential alterations in 5a-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 2005, 63:231-239.
3. Marks L.S., Roehrborn C.G., Wolford E., Wilson T.H. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. J Urol 2007 Apr, 177(4):1408-1413.
4. Andriole G on behalf of the REDUCE study group Headline results from the REduction by Dutasteride of prostate Cancer Events (REDUCE) study. Late breaking news May 2009, American Urology Association annual meeting, Chicago.
5. Fleshner N., Scott Lucia M., Egerdie B., Aaron L., Eure G., Nandy I., Black L., Rittmaster R. Dutasteride in localized prostate cancer management: the REDEEM randomized, double-blind, placebo-controlled trial. Lancet 2012, 10.1016/S0140-6736(11)61619-X.
6. Kurhanewicz J., Vigneron D., Carroll P., Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol 2008 January, 18(1):71-77.
7. Kirkham A.P., Emberton M., Allen C. How good is MRI at detecting and characterising cancer within the prostate?. Eur Urol 2006, Dec, 50(6):1163-1174.
8. Andriole G.L., Bostwick D.G., Brawley O.W., Gomella L.G., Marberger M., Montorsi F., et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010, 362:1192-1202.
9. Chung H.T., Noworolski S.M., Kurhanewicz J., Weinberg V., Roach Iii M. A pilot study of endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging changes with dutasteride in patients with low risk prostate cancer. BJU Int 2011 Oct, 108(8 Pt 2):E164-E170.
10. Lemaitre L., Puech P., Poncelet E., Bouyé S., Leroy X., Biserte J., Villers A. Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol 2009 Feb, 19(2):470-480.
11. Ballentine Carter H. Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl 2012 May, 14(3):355-360.
12. Haffner J., Lemaitre L., Puech P., Haber G.P., Leroy X., Jones J.S., Villers A. Role of magnetic resonance imaging before initial biopsy: Comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011, 108(8 Pt2):E171-E178.